Dynamic chemotherapy-induced upregulation of CXCR4 expression: a mechanism of therapeutic resistance in pediatric AML.
about
Role of Microenvironment in Resistance to Therapy in AMLTranslating leukemia stem cells into the clinical setting: Harmonizing the heterogeneity.Idelalisib sensitivity and mechanisms of disease progression in relapsed TCF3-PBX1 acute lymphoblastic leukemiaPlerixafor as a chemosensitizing agent in pediatric acute lymphoblastic leukemia: efficacy and potential mechanisms of resistance to CXCR4 inhibition.The intricate role of CXCR4 in cancer.Silencing of CXCR4 sensitizes triple-negative breast cancer cells to cisplatinDysregulated CXCR4 expression promotes lymphoma cell survival and independently predicts disease progression in germinal center B-cell-like diffuse large B-cell lymphomaLeukemia cell mobilization with G-CSF plus plerixafor during busulfan-fludarabine conditioning for allogeneic stem cell transplantationAntileukemia activity of the novel peptidic CXCR4 antagonist LY2510924 as monotherapy and in combination with chemotherapy.Bone metastasis and the metastatic niche.Tetraspanin 3 Is Required for the Development and Propagation of Acute Myelogenous LeukemiaTreatment of infant leukemias: challenge and promise.POL5551, a novel and potent CXCR4 antagonist, enhances sensitivity to chemotherapy in pediatric ALLTargeted positron emission tomography imaging of CXCR4 expression in patients with acute myeloid leukemiaTargeting the CXCL12/CXCR4 axis in acute myeloid leukemia: from bench to bedside.Adipocyte-derived players in hematologic tumors: useful novel targets?Myeloid malignancies and the microenvironment.CXCR4 Overexpression is a Poor Prognostic Factor in Pediatric Acute Myeloid Leukemia With Low Risk: A Report From the Japanese Pediatric Leukemia/Lymphoma Study Group.[177Lu]pentixather: Comprehensive Preclinical Characterization of a First CXCR4-directed Endoradiotherapeutic Agent.Clinical significance of chemokine receptor CXCR4 and mammalian target of rapamycin (mTOR) expression in patients with diffuse large B-cell lymphoma.Monoclonal Antibody Therapies for Hematological Malignancies: Not Just Lineage-Specific Targets.Leukemia Stem Cells Microenvironment.The bone-marrow niche in MDS and MGUS: implications for AML and MM.A phase 1 study of the CXCR4 antagonist plerixafor in combination with high-dose cytarabine and etoposide in children with relapsed or refractory acute leukemias or myelodysplastic syndrome: A Pediatric Oncology Experimental Therapeutics Investigato
P2860
Q27027502-9A2990A6-C035-464C-B944-EF5D8F50E06FQ30244186-3B4A7682-C97E-45AD-BC96-F533AD96A838Q30365752-E7BAB964-3895-40B6-AE86-4ADC562405CEQ34619171-B827A26D-2E09-4E3B-BDA8-FD63F5275EC7Q35067624-0A754B0E-04AC-4C7F-9E53-368E94EBE2B9Q35175999-6D184C20-26BD-4E43-A3EC-B626AD66F2CFQ35742364-B296792D-56EA-4F5B-B190-31B36187B8CBQ35812103-B4171783-E591-46F8-AF0D-C2644A147589Q35836868-706F049F-5560-43BF-BAE6-F8ACCB6CCAE2Q36259458-E6A7B9D7-1173-4445-8252-F1929D080CDFQ36331291-0E3BB157-8812-44D2-89CB-6F0C6655912EQ36508988-B2562A4B-A3DF-4725-8470-36DA863C749AQ36544455-DDF53978-BE1A-43EE-8314-8BCDB317D83CQ37140477-398E9C5C-8083-46E2-B1B3-CA3AA399510CQ37683451-3EDA5B86-3A0F-44B7-ADC4-9EF81EB8BDEFQ38259527-2596E807-BDE9-4263-9657-57C5ED7DB953Q39073878-99B6CC44-9B36-4741-926C-8FE3F8F8741AQ39803797-C9EB957E-F7C2-412C-9F3D-5B7C3BF6D19BQ41114242-ACC23485-CA2B-4674-8B19-290F38C5A6E2Q47737291-8F8A9210-C493-4C21-88F9-00CD93ED405BQ49539698-D01C0409-6F96-44F8-BDEE-3D1497726637Q50076185-F9669C0D-9CD3-4C80-AF0C-C09A860D474DQ50114615-F3EF4494-2BEB-46C1-9CF7-FB197A311625Q51058500-3F58E93A-AC42-438B-9C7E-FAACA31AA7D7
P2860
Dynamic chemotherapy-induced upregulation of CXCR4 expression: a mechanism of therapeutic resistance in pediatric AML.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 10 June 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Dynamic chemotherapy-induced u ...... c resistance in pediatric AML.
@en
Dynamic chemotherapy-induced u ...... c resistance in pediatric AML.
@nl
type
label
Dynamic chemotherapy-induced u ...... c resistance in pediatric AML.
@en
Dynamic chemotherapy-induced u ...... c resistance in pediatric AML.
@nl
prefLabel
Dynamic chemotherapy-induced u ...... c resistance in pediatric AML.
@en
Dynamic chemotherapy-induced u ...... c resistance in pediatric AML.
@nl
P2093
P2860
P1476
Dynamic chemotherapy-induced u ...... c resistance in pediatric AML.
@en
P2093
Daniel Magoon
Edward Allan R Sison
Emily McIntyre
Patrick Brown
P2860
P304
P356
10.1158/1541-7786.MCR-13-0114
P577
2013-06-10T00:00:00Z